BERN - Swiss drug prices sit near the top of international tables. Prices in the United States sit higher still. Washington wants that gap to shrink, and it is pressing manufacturers to sell new medicines more cheaply on the American market. For Roche and Novartis, lower prices on their largest market mean less revenue. The industry's answer, researchers say, is to ask other countries to pay more.
Hundreds of millions on Swiss premiums
A study published by researchers at ETH Zurich and the University of Zurich puts a Swiss figure on that shift. If Switzerland and other reference countries give in and raise prices, the extra cost for people who pay Swiss health premiums runs to hundreds of millions of francs a year. Co-author Kerstin Vokinger, a physician and lawyer, said Switzerland has to decide how it deals with the pressure from the United States.
The mechanism is the American "most-favored nation" idea: the United States compares its prices with a set of reference countries, and Switzerland is one of them. A higher Swiss price can then support a higher American price. A country that refuses the increase can become a less attractive place to launch a new drug. Vokinger said no country wants to be the one with the lowest prices and then find new medicines are not offered there. The result can be a round of countries outbidding one another.
Industry says the Swiss price now sets the American one
René Buholzer, head of Interpharma, the association of the large research companies, said the threat is already real. Because a price in the small Swiss market can become the price that counts in the large American one, he said, "we have to adapt". In his telling, that means higher Swiss prices, or innovative drugs will stop being offered here.
Interpharma says its members are already acting. A survey of the association found that a third of approved medicines are no longer being filed with the Federal Office of Public Health (FOPH) for reimbursement. The office gives a different count. Asked by SRF, it said the number of applications so far is similar to last year. Whether a company files is the company's decision. Patients only see the drug on the reimbursed list if that filing succeeds.
The US models are still unsettled
The study is built on the position in December 2025, and the American side has moved since. The Globe and Guard pricing models cover far fewer medicines than researchers assumed then. More of the action now sits in confidential contracts between companies and the US government, the so-called Generous models, whose terms are mostly unpublished. A records request by the consumer group Public Citizen has made part of that material public. It is still unclear whether Washington will carry the most-favored-nation models through. The industry is challenging one of them in court.
The FOPH says companies are already using the American comparison in price talks. It also says a general rise would be the wrong answer, because it is uncertain that the US models will last. Vokinger adds a second caution. As of today, Swiss prices are not among the lowest in the median of the reference basket, so they are not what sets the US price. They would start to matter if other countries raised theirs first.
Her recommendation is that Switzerland look for a common approach with other countries, rather than a race of unilateral increases. The study's extreme case is blunt: in an all-out price contest, American prices do not fall. Prices elsewhere rise, and the gain sits with the manufacturers.
The bill would land on premiums that are already going up. The government has set an average rise of about 5 percent for 2027. Medicine prices are only one line in that account. They are the line Washington has just made political.
